Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, vaccines and immunoinformatics approaches, and Immunotherapy and Immune Responses.
Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V <sub>H</sub> 1-2-rearranging mouse models
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in Humans
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Homologous and Heterologous Covid-19 Booster Vaccinations
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice
An antibody from single human V <sub>H</sub> -rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor
Targeted selection of HIV-specific antibody mutations by engineering B cell maturation
Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity
Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site